In addition to the different mutation levels and mutation subtypes in different cancer tissues, KRAS mutations may have different comutations, which may influence the function of KRAS and the occurrence and development of tumours. Analysing 1078 NSCLCs harbouring KRAS mutations, 557 patients (53.5%)...
KRAS mutationLung cancerLung adenocarcinomaErlotinib resistanceTargeted therapyMEK inhibitionSelumetinibPI3K inhibitionmTOR inhibitionHsp90 inhibitionKRAS-mutant lung cancers account for approximately 25 % of non-small cell lung carcinomas, thus representing an enormous burden of cancer worldwide. KRAS mutations...
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 6(1), 386. https://doi.org/10.1038/s41392-021-00780-4 Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010). C...
——KRAS mutation: from undruggable to druggable in cancer - Signal Transduction and Targeted Therapy ——治疗非小细胞肺癌,安进KRAS抑制剂达到80.6%疾病控制率 ——《Nature》:发现一种可有效抗癌并刺激免疫体统的抑制剂
19. Bekaii-Saab, T.S., Yaeger, R., Spira, A.I., Pelster, M.S., Sabari, J.K., Hafez, N., Barve, M., Velastegui, K., Yan, X., Shetty, A., et al. (2023). Adagrasib in Advanced Solid Tumors...
艾昆纬-KRAS突变:KRAS靶向治疗的关键选择管道开发和临床试验的最新进展(英)-2024.5-6页.doc,Article — May 2024 KRAS Mutation: An Update on Key Selected Pipeline Developments and Clinical Trials for KRAS Targeting Therapies IQVIA Pipeline Link/Trial Link SA
[5]https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [6]https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annua...
13. Dong ZY, Zhong WZ, Zhang XC, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017;23(12):3012-3024. doi:10.1158/1078-0432.CCR-16...
[25]. Zheng D, Wang R, Zhang Y, et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations[J]. OncoTargets and Therapy, 2016: 833-843. 本文作者:BioTalker “期待有那么一天,肿瘤医生不再对携带KRAS突变的患者束手无措”...
目前，Lumakras用于非小细胞肺癌的III期临床试验CodeBreak 200正在进行，用于其他携带KRASG12C突变实体瘤的试验也在逐步开展之中。参考文献：[1]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [2]. Cox A D,...